PSNL — Personalis, Inc.

Is PSNL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Oversold As of November 17, 2026

Personalis, Inc. (PSNL) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $14.80. The rating moved from Neutral to Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Personalis, Inc. operates in a high-growth genomics niche with differentiated sequencing and analytics that align with expanding precision oncology and biopharma outsourcing demand. Near-term upside drivers include contract wins, partnerships with large pharma, and increased adoption of biomarker-driven trials. Key constraints are execution and capital runway, strong competition from larger sequencing and lab service providers, and reimbursement/regulatory uncertainty. Market sentiment in the short run is cautious, which can amplify volatility, but secular demand for advanced genomic services supports multiple upside scenarios if execution and commercial traction continue.

Key factors

  • Specialized genomics and precision oncology sequencing capabilities with differentiated bioinformatics and assay validation
  • Addressable market exposure to oncology, biopharma R&D and companion diagnostic development supporting recurring revenue potential
  • Sector tailwinds from large-cap pharma M&A and partnerships that increase demand for outsourced genomics and biomarker services
  • Potential for partnership/contract wins with biopharma customers as drug development and precision medicine programs expand
  • Current market price that reflects growth-stage upside while still pricing in execution risk

Risks

  • Execution and cash runway risk for a smaller genomics services company; need for external capital could dilute shareholders or constrain investment
  • Intense competition from larger NGS/service providers (Illumina, Thermo Fisher, Guardant Health and other specialty labs) pressuring pricing and share gains
  • Reimbursement, regulatory and compliance uncertainty for clinical/diagnostic assays that could slow adoption or increase operating costs
  • Macroeconomic / risk-off market sentiment that reduces funding and slows biopharma outsourcing spend in near term
  • Customer concentration or loss of a large contract could materially reduce near-term revenue visibility
  • Limited or mixed public sentiment and liquidity which can amplify share volatility on news

See today's live rating, score and targets

Members see the live hourly rating for PSNL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.